• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Zimmer releases post-Biomet merger numbers

Zimmer releases post-Biomet merger numbers

March 10, 2015 By Brad Perriello

Zimmer releases post-Biomet merger numbers

Zimmer (NYSE:ZMH) today said its pending, $13.35 billion combination with Biomet will result in an entity that throws off annual profits of nearly $850 million on sales of about $8 billion.

Warsaw, Ind.-based Zimmer released a pro-forma financial estimate of the post-merger company, projecting profits of $849.4 million, or $4.16 per share, on sales of $7.95 billion.

The Zimmer-Biomet balance sheet will include cash & equivalents of $940.4 million, deferred income taxes of $3.87 billion and a whopping $11.78 billion in long-term debt, according to a regulatory filing.

The merger is awaiting a ruling by anti-trust regulators on the European Commission. Last month Zimmer revised the terms of the deal in a 2nd attempt to mollify the EuroZone.

The latest proposal is substantially the same as an offer Zimmer made last December to sell off parts of its European business. The assets that would be divested include a unicompartmental knee brand and an elbow brand in the European Economic Area and a total knee brand in 2 EEA countries, the company said at the time.

Although the EuroZone commission has until May 26 to make its call, Zimmer said it’s still confident in a 1st-quarter closing.

"We continue to work with the European Commission to finalize the remaining details for a remedy package. We also continue to make progress as it relates to the U.S. and Japan," Zimmer president & CEO David Dvorak said during a conference call with analysts, adding that Zimmer continues to expect "to be in a position to close the merger before the end of the 1st quarter."

The company reported profits of $156.6 million for the 4th quarter, or 91¢ per diluted share, on sales of $1.22 billion. That’s a 33.6% bottom-line slide compared with the 2013 4th quarter, on a sales decline of 1.4%.

For the full year, Zimmer reported profits of $720 million, or $4.19 per share, on sales of $4.67 billion, for a profit slide of 5.4% on 1.1% sales growth. Zimmer said it plans to provide guidance for 2015 in full after closing its acquisition of Biomet.

Filed Under: Mergers & Acquisitions, News Well, Orthopedics Tagged With: Biomet, Zimmer Biomet

More recent news

  • Pixee Medical reports first knee arthroplasty cases using its augmented reality nav tech
  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy